Emergent Biosolutions initiated with "outperform" - update
http://www.newratings.com/analyst_news/article_1450586.html
Cowen & Co
NEW YORK, January 4 (newratings.com) - Analysts at Cowen & Co initiate coverage of Emergent Biosolutions (ticker: EBS) with an "outperform" rating.
In a research note published yesterday, the analysts mention that following the termination of VaxGen’s contract for a recombinant anthrax vaccine, Emergent Biosolutions is expected to be given a considerable portion of the $877 million contract by HHS within the forthcoming six-to-twelve months. Emergent Biosolutions is developing other biodefense and commercial vaccine products targeting anthrax and botulinum, the analysts say. There is significant upside to Emergent Biosolutions’ share price over the next 12 months due to newsflow related to the company’s biodefense products, Cowen & Co adds.
Cowen & Co
NEW YORK, January 4 (newratings.com) - Analysts at Cowen & Co initiate coverage of Emergent Biosolutions (ticker: EBS) with an "outperform" rating.
In a research note published yesterday, the analysts mention that following the termination of VaxGen’s contract for a recombinant anthrax vaccine, Emergent Biosolutions is expected to be given a considerable portion of the $877 million contract by HHS within the forthcoming six-to-twelve months. Emergent Biosolutions is developing other biodefense and commercial vaccine products targeting anthrax and botulinum, the analysts say. There is significant upside to Emergent Biosolutions’ share price over the next 12 months due to newsflow related to the company’s biodefense products, Cowen & Co adds.
